Visit Quest Diagnostics® booth 808 | April 28-29, 2026 | Orlando, FL
We’re excited to participate in the 2026 Community Oncology Conference by the Community Oncology Alliance (COA), where leading experts will gather to advance care for cancer patients through science and collaboration.
We invite you to stop by Quest Diagnostics® booth 808 to learn how Haystack MRD®’s exceptionally accurate ctDNA testing brings confidence to residual disease detection, treatment monitoring, and recurrence detection in solid tumor cancers.
From the perioperative setting to recurrence surveillance, Haystack MRD tracks ctDNA across the treatment management journey—empowering oncologists to make informed, timely treatment decisions.
Haystack MRD offers
- Ultradeep sequencing that reads each molecule up to 1 million times
- Patented error-correction technology that ensures each variant is present on both DNA strands
- Exceptional sensitivity and specificity
- Confident MRD results for adjuvant decisions, treatment monitoring, and surveillance
- Clinical trial support including patient enrichment and stratification
- The power of Quest for a streamlined ordering process and accessibility
Let’s connect in Orlando
Visit Quest Diagnostics booth 808 to see how Haystack MRD is reshaping precision oncology through ctDNA insights.
Don’t miss the chance to see how Haystack MRD is advancing precision oncology. We look forward to meeting you at booth 808! Learn more about the conference here.
About Haystack MRD
Next-generation ctDNA detection with exceptional accuracy for confident MRD reporting
Haystack MRD is a tumor-informed ctDNA detection test for perisurgical and postsurgical measurement of residual disease in solid tumor settings. Superb sensitivity and specificity translate to better MRD detection for greater confidence when making key clinical decisions.
Purpose-built MRD technology developed by pioneers of cancer research
Haystack MRD was designed specifically for ultrasensitive ctDNA detection when testing for residual or recurrent disease. Better sensitivity means that patients are more likely to receive the right treatment at the right time, which can significantly improve outcomes and quality of life for patients who have been diagnosed with cancer.
Experience the power of Quest
From early detection screening to diagnosis, monitoring, and beyond, Quest offers routine to advanced testing along the cancer care continuum. Experience the efficiency of working with a single lab to improve the quality and speed of cancer care.
